OBJECTIVES: The Critical Illness Stress-Induced Immune Suppression prevention trial was a randomized, masked trial of zinc, selenium, glutamine, and metoclopramide compared with whey protein in delaying nosocomial infection in PICU patients. One fourth of study subjects were diagnosed with nosocomial lower respiratory infection, which contributed to subjects receiving antibiotics 74% of all patient days in the PICU. We analyzed diagnostic and treatment variability among the participating institutions and compared outcomes between nosocomial lower respiratory infection subjects (n = 74) and intubated subjects without nosocomial infection (n = 1 55). DESIGN: Post hoc analysis. SETTING: Eight hospitals in the Collaborative Pediatric Critical Care Research Network. PATIENTS: Critical Illness Stress-Induced Immune Suppression study subjects. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Variability across institutions existed in the frequency and manner by which respiratory secretion cultures were obtained, processed, and results reported. Most results were reported semiquantitatively, and both Gram stains and antibiotic sensitivities were frequently omitted. The nosocomial lower respiratory infection diagnosis was associated with increased PICU lengths of stay compared with those who were intubated without nosocomial infection (24 ± 19 vs 9 ± 6 d; p < 0.001) and antibiotic use (38 ± 29 vs 15 ± 20 antibiotics days; p < 0.001). Despite antibiotic treatment, the same bacteria persisted in 45% of follow-up cultures. CONCLUSIONS: The Critical Illness Stress-Induced Immune Suppression data demonstrate that the nosocomial lower respiratory infection diagnosis is associated with longer lengths of stay and increased antibiotic use, but there is considerable diagnostic and treatment variability across institutions. More rigorous standards for when and how respiratory cultures are obtained, processed, and reported are necessary. Bacterial persistence also complicates the interpretation of follow-up cultures.
OBJECTIVES: The Critical Illness Stress-Induced Immune Suppression prevention trial was a randomized, masked trial of zinc, selenium, glutamine, and metoclopramide compared with whey protein in delaying nosocomial infection in PICU patients. One fourth of study subjects were diagnosed with nosocomial lower respiratory infection, which contributed to subjects receiving antibiotics 74% of all patient days in the PICU. We analyzed diagnostic and treatment variability among the participating institutions and compared outcomes between nosocomial lower respiratory infection subjects (n = 74) and intubated subjects without nosocomial infection (n = 1 55). DESIGN: Post hoc analysis. SETTING: Eight hospitals in the Collaborative Pediatric Critical Care Research Network. PATIENTS: Critical Illness Stress-Induced Immune Suppression study subjects. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Variability across institutions existed in the frequency and manner by which respiratory secretion cultures were obtained, processed, and results reported. Most results were reported semiquantitatively, and both Gram stains and antibiotic sensitivities were frequently omitted. The nosocomial lower respiratory infection diagnosis was associated with increased PICU lengths of stay compared with those who were intubated without nosocomial infection (24 ± 19 vs 9 ± 6 d; p < 0.001) and antibiotic use (38 ± 29 vs 15 ± 20 antibiotics days; p < 0.001). Despite antibiotic treatment, the same bacteria persisted in 45% of follow-up cultures. CONCLUSIONS: The Critical Illness Stress-Induced Immune Suppression data demonstrate that the nosocomial lower respiratory infection diagnosis is associated with longer lengths of stay and increased antibiotic use, but there is considerable diagnostic and treatment variability across institutions. More rigorous standards for when and how respiratory cultures are obtained, processed, and reported are necessary. Bacterial persistence also complicates the interpretation of follow-up cultures.
Authors: Emily S Charlson; Kyle Bittinger; Andrew R Haas; Ayannah S Fitzgerald; Ian Frank; Anjana Yadav; Frederic D Bushman; Ronald G Collman Journal: Am J Respir Crit Care Med Date: 2011-06-16 Impact factor: 21.405
Authors: Pranita D Tamma; Alison E Turnbull; Aaron M Milstone; Christoph U Lehmann; Emily R M Sydnor; Sara E Cosgrove Journal: Clin Infect Dis Date: 2011-05-02 Impact factor: 9.079
Authors: Lucy B Palmer; Gerald C Smaldone; John J Chen; Daniel Baram; Tao Duan; Melinda Monteforte; Marie Varela; Ann K Tempone; Thomas O'Riordan; Feroza Daroowalla; Paul Richman Journal: Crit Care Med Date: 2008-07 Impact factor: 7.598
Authors: Kathleen L Meert; Ralph Delius; Beth S Slomine; James R Christensen; Kent Page; Richard Holubkov; J Michael Dean; Frank W Moler Journal: Ann Thorac Surg Date: 2018-12-14 Impact factor: 4.330
Authors: Katherine Cashen; Ron Reeder; Heidi J Dalton; Robert A Berg; Thomas P Shanley; Christopher J L Newth; Murray M Pollack; David Wessel; Joseph Carcillo; Rick Harrison; J Michael Dean; Robert Tamburro; Kathleen L Meert Journal: Perfusion Date: 2018-04-11 Impact factor: 1.972